• News
  • SAN DIEGO
  • Health

Sorrento Therapeutics adds Amar Singh as executive VP

Sorrento Therapeutics Inc. (Nasdaq: SRNE) has appointed Amar Singh to be its executive vice president and chief business officer, the late-stage clinical oncology company reported Wednesday.

Singh, who was previously senior vice president and chief business officer at Synta Pharmaceuticals, will be responsible for overseeing Sorrento's partnering activities, according to a release.

Singh has worked more than 25 years in business and commercial development. He joins the company as it continues its work on most advanced cell division inhibitor Cynviloq. He holds a master's degree in business administration from the Stern School of Business at New York University and a bachelor's degree from the University of North Carolina at Chapel Hill.

"Amar joins us at a pivotal phase in our company's growth as we advance Cynviloq into its registrational trial and continue the development of resiniferatoxin," Dr. Henry Ji, president and CEO of Sorrento, said. "His successful track record of initiating and closing complex transactions, in addition to managing strategic alliances, will be particularly useful for both our clinical as well as early-stage programs."

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

User Response
0 UserComments

Leave Your Comment

Comments are moderated by SDDT, in accordance with the SDDT Comment Policy, and may not appear on this commentary until they have been reviewed and deemed appropriate for posting. Also, due to the volume of comments we receive, not all comments will be posted.

SDDT Comment Policy: SDDT encourages you to add a comment to this discussion. You may not post any unlawful, threatening, defamatory, obscene, pornographic or other material that would violate the law. All comments should be relevant to the topic and remain respectful of other authors and commenters. You are solely responsible for your own comments, the consequences of posting those comments, and the consequences of any reliance by you on the comments of others. By submitting your comment, you hereby give SDDT the right, but not the obligation, to post, air, edit, exhibit, telecast, cablecast, webcast, re-use, publish, reproduce, use, license, print, distribute or otherwise use your comment(s) and accompanying personal identifying and other information you provide via all forms of media now known or hereafter devised, worldwide, in perpetuity. SDDT Privacy Statement.

Sorrento Therapeutics Inc.

Company Website

6042 Cornerstone Ct. West Ste., B
San Diego, CA 92121

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
SRNE
8.98
  0.38  
+ 4.42%
427,415,000
26.8
3.41

Sorrento Therapeutics Inc. Executive(s):

Henry Ji

  • Chief Executive Officer

Richard Vincent

  • Chief Financial Officer

Similar Companies

NAICS - 541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)